| Date | Name | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| Aug 02, 2012 |
SVP Clinical Development & Reg
|
SVP Clinical Development & Reg | Form 4 | Other acquisition or disposition | -- | -- | 1,532 |
| Aug 01, 2012 |
SVP Clinical Development & Reg
|
SVP Clinical Development & Reg | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 4,562 | $21.92 | 19,706 |
| Aug 01, 2012 |
SVP Clinical Development & Reg
|
SVP Clinical Development & Reg | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 10,428 | $15.64 | 30,134 |
| Aug 01, 2012 |
SVP Clinical Development & Reg
|
SVP Clinical Development & Reg | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 10,428 | -- | -- |
| Aug 01, 2012 |
SVP Clinical Development & Reg
|
SVP Clinical Development & Reg | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 4,562 | -- | -- |
| Jul 27, 2012 |
SVP Clinical Development & Reg
|
SVP Clinical Development & Reg | Form 4 | Other acquisition or disposition | -- | -- | 1,532 |
| Jul 26, 2012 |
SVP Clinical Development & Reg
|
SVP Clinical Development & Reg | Form 4 | Open market or private sale of non-derivative or derivative security | 4,519 | $130.40 | 17,644 |
| Jul 26, 2012 |
SVP Clinical Development & Reg
|
SVP Clinical Development & Reg | Form 4 | Open market or private sale of non-derivative or derivative security | 2,500 | $131.07 | 15,144 |
| Jul 25, 2012 |
SVP Clinical Development & Reg
|
SVP Clinical Development & Reg | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 15,000 | $16.80 | 30,144 |
| Jul 25, 2012 |
SVP Clinical Development & Reg
|
SVP Clinical Development & Reg | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 1,987 | $126.76 | 28,157 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.